View Clinical Trial (Medical Research Study)

A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma - NCT01015911-48201(Clinical Trial 444856)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Detroit
State:  
MI
Zip Code: 48201
Conditions: Carcinoma, Renal Cell - Lymphoma, Non-Hodgkin
Purpose: This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in patients with CD70-positive relapsed or refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.
Study summary:
Criteria: Inclusion Criteria: - Pathologically-confirmed diagnosis of NHL or RCC - Relapsed, refractory, or progressive disease following at least 1 prior systemic therapy - Confirmed CD70 expression - Measurable disease, defined as at least 1 lesion >1.5 cm in the greatest transverse diameter for patients with NHL, and at least 1 non-resectable tumor lesion > or equal to 10 mm in diameter for patients with RCC Exclusion Criteria: - Previously received an allogeneic transplant - History of another primary malignancy that has not been in remission for at least 3 years - Prior anti-CD70-directed therapy
Study is available at: Karmanos Cancer Institute / Wayne State University
Detroit, MI 48201
United States

Primary Contact:
Devon Britton
Email: brittond@karmanos.org
Phone: 313-576-9381

Secondary Contact:
Terri Lowe
Email: clinicaltrials@seagen.com
Phone: 866-333-7436
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.